

I hereby certify that this correspondence is being deposited with the United States Postal Service as *First Class Mail* in an envelope addressed to:

Commissioner for Patents  
P O Box 1450  
Alexandria, VA 22313-1450

On June 8, 2007

MORGAN, LEWIS & BOCKIUS LLP

By Kathryn A. Degliantoni  
Kathryn A. Degliantoni

PATENT  
Attorney Docket No.: 66254-5003-US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

COUNSELL, *et al.*

Application No.: 10/692,311

Filed: October 23, 2003

For: BLOOD POOL CARRIER FOR  
LIPOPHILIC AGENTS

Customer No.: 43850

Confirmation Number: 8570

Examiner: Jones, Dameron L.

Art Unit: 1618

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO/SB/8A are being called to the attention of the Examiner. In accordance with CFR 1.98(2)(ii), copies of the U.S. patents and U.S. patent application publications are not enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

The Commissioner is authorized to deduct \$180 from the undersigned's Deposit Account No. 50-0310 since this IDS is being filed after the issuance of an Office Action. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
\_\_\_\_\_  
Ada Wong, Reg. No. 55,740  
for

Jeffrey S. Mann, Ph.D.  
Reg. No. 42,837

MORGAN, LEWIS & BOCKIUS LLP  
Two Palo Alto Square  
3000 El Camino Real, Ste. 700  
Palo Alto, CA 94306  
Tel. (415) 442-1000  
Direct Dial: (415) 442-1490  
eFAX: (650) 843-4001  
e-mail: awong@morganlewis.com  
ATTACHMENTS

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/692,311
				<i>Filing Date</i>	October 23, 2003
				<i>First Named Inventor</i>	Counsell, Raymond E.
				<i>Art Unit</i>	1618
				<i>Confirmation No.</i>	8570
				<i>Examiner Name</i>	Jones, Dameron L.
(use as many sheets as necessary)				<i>Attorney Docket Number</i>	66254-3001-US01
Sheet			of	2	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,873,075	10/10/1989	Counsell, et al.	
	A2	4,957,729	09/18/1990	Counsell, et al.	
	A3	5,043,164	08/27/1991	Huang, et al.	
	A4	5,093,042	03/03/1992	Counsell, et al.	
	A5	5,116,599	05/26/1992	Rogers, Jr., et al.	
	A6	5,234,680	08/10/1993	Rogers, Jr., et al.	
	A7	5,326,552	07/05/1994	Na, et al.	
	A8	5,478,860	12/26/1995	Wheeler, et al.	
	A9	5,543,158	08/06/1996	Gref, et al.	
	A10	5,851,510	12/22/1998	Counsell, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A11	DE	44 08 011	C1	1995-11			<input checked="" type="checkbox"/>
	A12	WO	93/019738		1993-10-14	Liposome Technology, Inc.		<input type="checkbox"/>
	A13	WO	94/07466		1993-04-14	Liposome Technology, Inc.		<input type="checkbox"/>
	A14	WO	95/31181		1995-11-23	The Board Of Regents Of The University Of Michigan Counsell		<input type="checkbox"/>
	A15	WO	96/34598		1996-11-07	Polymasc Pharmaceuticals Plc		<input type="checkbox"/>
	A16	WO	97/13499		1997-04-17	The University Of British Columbia		<input type="checkbox"/>
	A17	WO	97/40858		1997-11-06	Imarx Pharmaceutical Corp.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	A18	Counsell, <i>et al.</i> , "Principles of Medicinal Chemistry, 4th Edition," edited by William Foye, Chapter 45, 1995.			
	A19	Liu, <i>et al.</i> , "Long-Circulating Emulsions (Oil-in-Water) as Carriers for Lipophilic Drugs," <i>Pharm. Res.</i> , 12:1060-1062 (1995)			
	A20	<u>Handbook of Chemistry and Physics</u> , 58th Edition, pages B-303-305, CRC Press, 1977-1978			

Examiner Signature	1-SF/7348634.1	Date Considered	
--------------------	----------------	-----------------	--

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	
			10/692,311	
			Filing Date	
			October 23, 2003	
			First Named Inventor	
			Counsell, Raymond E.	
(use as many sheets as necessary)			Art Unit	
			1618	
			Confirmation No.	
Sheet <b>2</b> of <b>2</b>			Examiner Name	
			Jones, Dameron L.	
			Attorney Docket Number	
			66254-3001-US01	

FOREIGN PATENT DOCUMENTS							T <sup>o</sup>	
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A21		Kirpotin, <i>et al.</i> , "Liposomes With Detachable Polymer Coating: Destabilization and Fusion of Dioleoylphosphatidylethanolamine Vesicles Triggered by Surface-Grafted Poly(ethylene Glycol)," <i>FEBS Letters</i> , 388:115-118 (1996)					
	A22		Sachse, <i>et al.</i> , "Biodistribution and Computed Tomography Blood-Pool Imaging Properties of Polyethylene Glycol-Coated Iopromide-Carrying Liposomes," <u>Invest. Radio.</u> , 32(1):44-50 (1997)					
	A23		Schneider, <i>et al.</i> , "Surface Modification of Continuously Extruded Contrast-Carrying Liposomes: Effect on Their Physical Properties," <u>International Journal of Pharmaceutics</u> , 132:9-21 (1996)					
	A24		Scherphof, <i>et al.</i> , "Intrahepatic Distribution of Long-Circulating Liposomes Containing Poly(Ethylene Glycol) Distearoyl Phosphatidylethanolamine," <u>Journal of Liposome Research</u> , 4(1):213-228 (1994)					
	A25		Weichert, <i>et al.</i> , "Potential Tumor- or Organ-Imaging Agents. 26. Polyiodinated 2-Substituted Triacylglycerols as Hepatographic Agents," <u>J. Med. Chem.</u> , 29:1674-1682 (1986)					
	A26		Weichert, <i>et al.</i> , "Potential Tumor- or Organ-Imaging Agents. 27. Polyiodinated 1,3-Disubstituted and 1,2, 3-Trisubstituted Triacylglycerols," <u>J. Med. Chem.</u> , 29:2457-2465 (1986)					
	A27		Weichert, <i>et al.</i> , "Polyiodinated Triglyceride Analogs as Potential Computer Tomography Imaging Agents for the Liver," <u>J. Med. Chem.</u> , 38:636-646 (1995)					
	A28		Wheeler, <i>et al.</i> , "Polyethylene Glycol Modified Phospholipids Stabilize Emulsions Prepared From Triacylglycerol," <u>J. Pharm. Sci.</u> , 83:1558-1564 (1994)					

Examiner Signature	I-SF/7348634.1	Date Considered	
--------------------	----------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.